Lung Cancer (NSCLC)PRACTICALNCT07202260
Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung
An observational study of Lung Cancer (NSCLC) and Lung Cancer (SCLC), run by The Christie NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer (NSCLC), Lung Cancer (SCLC)
- How many people
- 80 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 3 Jul 2025to 1 Dec 2028
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients over 18 years of age, with stage I, II or III lung cancer undergoing curative-intent radiotherapy at the Christie Hospital.
Who may be able to join
None listed.
Who cannot join
- Include patients with stage IV disease who are receiving non-curative intent radiotherapy
- There are no exclusion criteria relating to upper age limit or comorbidities.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
The Christie NHS Foundation Trust
Withington, Greater Manchester, M20 1BX
About this study
Official title: Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung (The PRACTICAL Study)
This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.
Read the detailed description
By studying detailed patient data, researchers aim to find the best ways to treat these patients while reducing short- and long-term side effects. The findings will help refine radiotherapy treatments, ensuring they are as safe and effective as possible. Additionally, the results will provide doctors with better information to help patients understand the potential risks and benefits of their treatment options.
- Conditions
- Lung Cancer (NSCLC), Lung Cancer (SCLC)
- Keywords
- radiotherapy, interstitial lung disease, vascular invasion, re-irradiation, rare histology
- Medical subject headings
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Interstitial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with co-existing interstitial lung disease | Not described | |
| Patients who undergo radiotherapy twice to the same area (reirradiation). | Not described | |
| Patients with the less common or rare types of lung cancer | Not described | |
| Patients with cancer invading large blood vessels. | Not described | |
| Patients with oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies. | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acute and late toxicity
- Acute (<90 days post radiotherapy) and late (> 90 days post radiotherapy) toxicity according to common terminology criteria for adverse events (CTCAE) V5.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2025
- Study start3 Jul 2025
- Primary completion15 Jul 2028 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer (NSCLC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- The Christie NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07202260
- Sponsor's protocol ID
- CFTSP 230
- Acronym
- PRACTICAL
- Status last verified
- Sep 2025
- First submitted
- 20 Feb 2025
- Last updated
- 1 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung (The PRACTICAL Study)
- ClinicalTrials.gov ID
- NCT07202260
- Acronym / sponsor ID
- PRACTICAL / CFTSP 230
- Conditions
- Lung Cancer (NSCLC), Lung Cancer (SCLC)
- Keywords
- radiotherapy, interstitial lung disease, vascular invasion, re-irradiation, rare histology
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- The Christie NHS Foundation TrustUniversity, hospital or other
- Study start
- 3 Jul 2025 (actual)
- Primary completion
- 15 Jul 2028 (estimated)
- Study completion
- 1 Dec 2028 (estimated)
- First posted
- 1 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.
Detailed description
By studying detailed patient data, researchers aim to find the best ways to treat these patients while reducing short- and long-term side effects. The findings will help refine radiotherapy treatments, ensuring they are as safe and effective as possible. Additionally, the results will provide doctors with better information to help patients understand the potential risks and benefits of their treatment options.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Patients with co-existing interstitial lung disease | – | – |
| Patients who undergo radiotherapy twice to the same area (reirradiation). | – | – |
| Patients with the less common or rare types of lung cancer | – | – |
| Patients with cancer invading large blood vessels. | – | – |
| Patients with oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies. | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients over 18 years of age, with stage I, II or III lung cancer undergoing curative-intent radiotherapy at the Christie Hospital.
Key inclusion criteria (0 listed)
Key exclusion criteria (2 listed)
- Include patients with stage IV disease who are receiving non-curative intent radiotherapy
- There are no exclusion criteria relating to upper age limit or comorbidities.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Acute and late toxicity
Time frame: 2 years
- Acute (<90 days post radiotherapy) and late (> 90 days post radiotherapy) toxicity according to common terminology criteria for adverse events (CTCAE) V5.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2025.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer (NSCLC)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer (NSCLC) and Lung Cancer (SCLC), run by The Christie NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acute and late toxicity (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2025.